INR 5839.8
(-0.17%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 30 Million INR | -7.98% |
2022 | 32.6 Million INR | -11.65% |
2021 | 36.9 Million INR | -23.6% |
2020 | 48.3 Million INR | -87.57% |
2019 | 388.5 Million INR | -63.21% |
2018 | 1.05 Billion INR | 67.33% |
2017 | 631.1 Million INR | 76.59% |
2016 | 357.38 Million INR | -14.92% |
2015 | 420.03 Million INR | 64.26% |
2014 | 255.71 Million INR | 51.55% |
2013 | 168.73 Million INR | -45.52% |
2012 | 309.71 Million INR | -41.3% |
2011 | 527.6 Million INR | 128.94% |
2010 | 230.45 Million INR | -29.84% |
2009 | 328.48 Million INR | -84.7% |
2008 | 2.14 Billion INR | 149.43% |
2007 | 860.79 Million INR | -44.09% |
2006 | 1.53 Billion INR | 2.51% |
2005 | 1.5 Billion INR | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 Q4 | - INR | -100.0% |
2023 Q3 | 30 Million INR | 0.0% |
2023 Q2 | - INR | -100.0% |
2023 Q1 | 50 Million INR | 0.0% |
2023 FY | 30 Million INR | -7.98% |
2022 Q2 | - INR | -100.0% |
2022 Q3 | 32.6 Million INR | 0.0% |
2022 Q4 | - INR | -100.0% |
2022 FY | 32.6 Million INR | -11.65% |
2022 Q1 | 33 Million INR | 0.0% |
2021 Q4 | - INR | -100.0% |
2021 Q3 | 36.9 Million INR | 0.0% |
2021 Q2 | - INR | -100.0% |
2021 FY | 36.9 Million INR | -23.6% |
2021 Q1 | 41.7 Million INR | 0.0% |
2020 Q1 | 50.9 Million INR | 0.0% |
2020 FY | 48.3 Million INR | -87.57% |
2020 Q2 | - INR | -100.0% |
2020 Q3 | 48.3 Million INR | 0.0% |
2020 Q4 | - INR | -100.0% |
2019 Q3 | 388.5 Million INR | 0.0% |
2019 Q1 | 135.3 Million INR | 0.0% |
2019 FY | 388.5 Million INR | -63.21% |
2019 Q4 | - INR | -100.0% |
2019 Q2 | - INR | -100.0% |
2018 Q3 | 1.05 Billion INR | 0.0% |
2018 FY | 1.05 Billion INR | 67.33% |
2018 Q4 | - INR | -100.0% |
2017 FY | 631.1 Million INR | 76.59% |
2017 Q4 | - INR | 0.0% |
2016 FY | 357.38 Million INR | -14.92% |
2015 FY | 420.03 Million INR | 64.26% |
2014 Q3 | 261.2 Million INR | 0.0% |
2014 FY | 255.71 Million INR | 51.55% |
2013 FY | 168.73 Million INR | -45.52% |
2013 Q3 | 178.7 Million INR | 0.0% |
2012 Q3 | 326.1 Million INR | 0.0% |
2012 FY | 309.71 Million INR | -41.3% |
2011 FY | 527.6 Million INR | 128.94% |
2010 FY | 230.45 Million INR | -29.84% |
2009 FY | 328.48 Million INR | -84.7% |
2008 FY | 2.14 Billion INR | 149.43% |
2007 FY | 860.79 Million INR | -44.09% |
2006 FY | 1.53 Billion INR | 2.51% |
2005 FY | 1.5 Billion INR | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Sigachi Industries Limited | 1.43 Billion INR | 97.903% |
Ind-Swift Limited | 10.13 Billion INR | 99.704% |
Bajaj HealthCare Limited | 3.32 Billion INR | 99.099% |
Sakar Healthcare Limited | 793.51 Million INR | 96.219% |
Aurobindo Pharma Limited | 66.47 Billion INR | 99.955% |
Innova Captab Limited | 2.45 Billion INR | 98.776% |
AstraZeneca Pharma India Limited | 45.98 Million INR | 34.757% |
Morepen Laboratories Limited | 289.99 Million INR | 89.655% |
Mankind Pharma Limited | 2.07 Billion INR | 98.552% |
Sequent Scientific Limited | 4.87 Billion INR | 99.385% |
Wanbury Limited | 1.16 Billion INR | 97.425% |
Laurus Labs Limited | 25.77 Billion INR | 99.884% |
Nectar Lifesciences Limited | 6.35 Billion INR | 99.528% |
Glenmark Life Sciences Limited | 171.48 Million INR | 82.505% |
Alembic Limited | 91.5 Million INR | 67.213% |
Hikal Limited | 8.17 Billion INR | 99.633% |
Alembic Pharmaceuticals Limited | 5.13 Billion INR | 99.415% |
Neuland Laboratories Limited | 953.89 Million INR | 96.855% |
J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 99.206% |
Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 99.756% |
IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 90.842% |
Themis Medicare Limited | 957.92 Million INR | 96.868% |
RPG Life Sciences Limited | - INR | -Infinity% |
Zydus Lifesciences Limited | 8.04 Billion INR | 99.627% |
Lupin Limited | 29.21 Billion INR | 99.897% |
Amrutanjan Health Care Limited | 17.28 Million INR | -73.581% |
Wockhardt Limited | 23.56 Billion INR | 99.873% |
Vaishali Pharma Limited | 134.91 Million INR | 77.764% |
Aarti Pharmalabs Limited | 2.85 Billion INR | 98.948% |
Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | 66.447% |
Jubilant Pharmova Limited | 36.64 Billion INR | 99.918% |
FDC Limited | 205.18 Million INR | 85.379% |
Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 99.85% |
Kilitch Drugs (India) Limited | 316.46 Million INR | 90.52% |
Eris Lifesciences Limited | 27.81 Billion INR | 99.892% |
Venus Remedies Limited | 413.3 Million INR | 92.741% |
ZIM Laboratories Limited | 1.08 Billion INR | 97.243% |
Bliss GVS Pharma Limited | 998.4 Million INR | 96.995% |
Par Drugs and Chemicals Limited | - INR | -Infinity% |
Caplin Point Laboratories Limited | 19.7 Million INR | -52.284% |
Shilpa Medicare Limited | 9.37 Billion INR | 99.68% |
Albert David Limited | 33.24 Million INR | 9.753% |
Ajanta Pharma Limited | 352.8 Million INR | 91.497% |
Hester Biosciences Limited | 2.44 Billion INR | 98.772% |
Suven Pharmaceuticals Limited | 649.96 Million INR | 95.384% |
Solara Active Pharma Sciences Limited | 10.11 Billion INR | 99.703% |
Gufic Biosciences Limited | 3.32 Billion INR | 99.099% |
Windlas Biotech Limited | 36.41 Million INR | 17.605% |
Procter & Gamble Health Limited | 95.6 Million INR | 68.619% |
Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | 90.431% |
Mangalam Drugs & Organics Limited | 984.92 Million INR | 96.954% |
Granules India Limited | 13.15 Billion INR | 99.772% |
Aarti Drugs Limited | 5.64 Billion INR | 99.468% |
Bal Pharma Limited | 1.39 Billion INR | 97.852% |
Alkem Laboratories Limited | 14.18 Billion INR | 99.788% |
Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.908% |
Lincoln Pharmaceuticals Limited | 10.66 Million INR | -181.215% |
Medicamen Biotech Limited | 308.17 Million INR | 90.265% |
Unichem Laboratories Limited | 2.47 Billion INR | 98.788% |
Bafna Pharmaceuticals Limited | 243.89 Million INR | 87.7% |
Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -583.527% |
Valiant Laboratories Limited | 767.08 Million INR | 96.089% |
Orchid Pharma Limited | 1.35 Billion INR | 97.781% |
Medico Remedies Limited | 80.5 Million INR | 62.735% |
Ind-Swift Laboratories Limited | 166.21 Million INR | 81.951% |
Ipca Laboratories Limited | 14.38 Billion INR | 99.791% |
Brooks Laboratories Limited | 56.41 Million INR | 46.826% |
Syncom Formulations (India) Limited | 724.86 Million INR | 95.861% |
Piramal Enterprises Limited | 535.85 Billion INR | 99.994% |
Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.925% |
NATCO Pharma Limited | 3.71 Billion INR | 99.192% |
Suven Life Sciences Limited | 7.09 Million INR | -322.714% |
Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 98.449% |
Strides Pharma Science Limited | 25.16 Billion INR | 99.881% |
Indoco Remedies Limited | 6.71 Billion INR | 99.554% |
Alpa Laboratories Limited | 52.46 Million INR | 42.819% |
Lasa Supergenerics Limited | 220.76 Million INR | 86.411% |
Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 95.094% |